Drugmaker Remedy for Scandal Is More Chinese for China
This article is for subscribers only.
Drugmakers are putting more Chinese nationals in important positions in the country to avoid the kind of bribery scandal plaguing GlaxoSmithKline Plc, according to the head of Europe’s pharmaceutical industry group.
Chinese police handed a case against Glaxo’s China unit to prosecutors last month, alleging that Mark Reilly, a British national who previously led the group, helped set up and expand sales departments that offered bribes to doctors in return for prescribing drugs. The London-based company also faces a U.K. criminal probe.